Results 61 to 70 of about 521,452 (268)

Long term outcome of allogeneic stem cell transplantation for patients with Fanconi Anemia

Journal of Taibah University Medical Sciences, 2023
Khayati Malak, Mekni Sabrine, Torjemane Lamia, Belloumi Dorra, Kanoun Rimmel Yousra, Ben Yaiche Insaf, Ouerghi Rihab, Turki Ines, Ladeb Saloua, Ben Abdeljelil Nour, Ben Othmane Tarek   +10 more
doaj   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

PB2200: CLONAL HEMATOPOIESIS AT THE CROSSROADS OF INFLAMMATORY BOWEL DISEASES AND HEMATOLOGICAL MALIGNANCIES: A BIOLOGICAL LINK?

HemaSphere, 2022
C. Cumbo, F. Tarantini, A. Zagaria, L. Anelli, C. F. Minervini, N. Coccaro, G. Tota, L. Impera, E. Parciante, M. R. Conserva, I. Redavid, P. Carluccio, M. Delia, A. Giordano, C. Longo, T. Perrone, A. Russo Rossi, G. Specchia, P. Musto, F. Albano   +19 more
doaj   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy

Haematologica, 2013
Spindle poison-based therapy is of only limited benefit in acute myeloid leukemia while lymphoblastic leukemia/lymphoma responds well. In this study, we demonstrated that the spindle assembly checkpoint protein BubR1 was down-regulated in the vast ...
Dominik Schnerch, Andrea Schmidts, Marie Follo, Josefina Udi, Julia Felthaus, Dietmar Pfeifer, Monika Engelhardt, Ralph Wäsch   +7 more
doaj   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

P468: MRD AS A BIOMARKER FOR RESPONSE TO DONOR LYMPHOCYTE INFUSION AFTER AL-LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

HemaSphere, 2022
K. Teich, M. Stadler, R. Gabdoulline, C. Wienecke, B. Heida, P. Klement, K. Büttner, L. Venturini, M. Wichmann, W. Puppe, C. Schultze-Florey, G. Beutel, M. Eder, A. Ganser, M. Heuser, F. Thol   +15 more
doaj   +1 more source

Blinatumomab-induced remission followed by haploidentical transplantation in pediatric relapsed/refractory pre-B ALL: a multicenter study in Mexico

Frontiers in Oncology
BackgroundPrecursor B-cell acute lymphoblastic leukemia (pre-B ALL) is the most common pediatric cancer worldwide, with cure rates exceeding 85% in high-income countries.
Alberto Olaya-Vargas, Alberto Olaya-Vargas, Haydee Salazar-Rosales, Yadira Melchor-Vidal, Martín Pérez-García, Annecy Herver-Olivares, Gerardo López-Hernández, Nideshda Ramírez-Uribe, Nideshda Ramírez-Uribe, Cesar Galván-Díaz, Irlanda Campos-Pérez, Pilar Cubria-Juárez, Angeles Del Campo-Martínez, Norma López-Santiago, Rocio Cárdenas-Cardos, Rocio Cárdenas-Cardos, Cesar Cárdenas-Pérez Gallardo, Ignacio Mora-Magaña, Jaime Shalkow-Klincovstein   +18 more
doaj   +1 more source

A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant

Hematology Reports, 2019
A unique case of primary refractory FLT3-itd mutated acute myeloid leukemia in an elderly patient, who achieved completed morphological remission, and FLT3-itd negativity, following 9 cycles of azacitadine in combination with escalating doses of donor ...
Claire Horgan, Alexandros Kanellopoulos, Shankara Paneesha, Bhuvan Kishore, Richard Lovell, Emmanouil Nikolousis   +5 more
doaj   +1 more source